Capitol Street, NW., 9th Floor. Interested parties may submit comments on each agreement to the Secretary, Federal Maritime Commission, Washington, DC 20573, within 10 days after the date of the **Federal Register** in which this notice appears. The requirements for comments are found in § 572.603 of Title 46 of the Code of Federal Regulations. Interested persons should consult this section before communicating with the Commission regarding a pending agreement.

Agreement No.: 202–011432–003.

Title: Pacific Latin America Agreement.

Parties:

Sea-Land Service, Inc.
Central American Container Line, S.A.
A.P. Moller-Maersk Line

Synopsis: The proposed amendment deletes Central America Container Line, S.A., changes the notification period for independent action from two days to five days and authorizes the Conference Chairman or his designee to sign and file any amendments to the basic Agreement.

Dated: February 13, 1995.

By Order of the Federal Maritime Commission.

Joseph C. Polking,

Secretary.

[FR Doc. 95–3981 Filed 2–16–95; 8:45 am]

BILLING CODE 6730–01–M

FEDERAL MARITIME COMMISISON

[Docket No. 95–03]

Puerto Rico Frieght Systems, Inc. v. R & S Trading and J.C. Trading; Notice of Filing of Complaint and Assignment

Notice is given that a complaint filed by Puerto Rico Freight Systems, Inc. (''Complainant'') against R & S Trading and J.C.Trading (''Respondents'') was served February 14, 1995. Complainant alleges that Respondents have violated sections 3, 14, 15, 16, 17, and 18 of the Shipping Act of 1916, 46 U.S.C. app. 804, 812, 814, 815, 816 and 817(b)(1), by issuing false manifests, shipping materials in containers which are not manifested or declared by Respondents, operating without a tariff, waiving fees for ocean freight, competing with other freight operators who adhere to a tariff to their disadvantage, and operating without bills of lading.

This proceeding has been assigned to the office of Administrative Law Judges. Hearing in this matter, if any is held, shall commence within the time limitations prescribed in 46 CFR 502.61, and only after consideration has been given by the parties and the presiding officer to the use of alternative forms of dispute resolution. The hearing shall include oral testimony and cross-examination in the discretion of the presiding officer only upon proper showing that there are genuine issues of material fact that cannot be resolved on the basis of sworn statements, affidavits, depositions, or other documents or that the nature of the matter in issue is such that an oral hearing and cross-examination are necessary for the development of an adequate record. Pursuant to the further terms of 46 CFR 502.61, the initial decision of the presiding officer in this proceeding shall be issued by February 14, 1996, and the final decision of the Commission shall be issued by June 14, 1996.

Joseph C. Polking,

Secretary.

[FR Doc. 95–4027 Filed 2–16–95; 8:45 am]

BILLING CODE 6730–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

National Committee on Vital and Health Statistics: Meeting

Pursuant to Pub. L. 92–463, the National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), announces the following committee meeting.

Name: National Committee on Vital and Health Statistics (NCVHS).

Times and Dates: 1 p.m.–5 p.m., March 8, 1995; 9 a.m.–5 p.m., March 9, 1995; 9 a.m.–3 p.m., March 10, 1995.

Place: Room 703A, Hubert H. Humphrey Building, 200 Independence Avenue, SW, Washington, D.C. 20201.

Status: Open.

Purpose: The purpose of this meeting is for the committee to consider reports from each NCVHS subcommittee; to receive reports from offices of the Department of Health and Human Services; to explore information needs for health reform; and to address new business as appropriate.

Contact Person for More Information: Substantive program information as well as summaries of the meeting and a roster of committee members may be obtained from Gail F. Fisher, Ph.D., Executive Secretary, NCVHS, NCHS, CDC, Room 1100, Presidential Building, 6525 Belcrest Road, Hyattsville, Maryland 20782, telephone 301/436–7050.

Dated: February 13, 1995.

William H. Gimson,

Acting Associate Director for Policy Coordination, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95–3999 Filed 2–16–95; 8:45 am]

BILLING CODE 4163–18–M

Food and Drug Administration

[Docket No. 95M–0023]

Molecular Biosystems, Inc.; Premarket Approval of Albunex®

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing its approval of the application by Molecular Biosystems, Inc., San Diego, CA, for premarket approval, under the Federal Food, Drug, and Cosmetic Act (the act), of Albunex®. After reviewing the recommendation of the Radiological Devices Panel, FDA's Center for Devices and Radiological Health (CDRH) notified the applicant, by letter of August 5, 1994, of the approval of the application.

DATES: Petitions for administrative review by March 20, 1995.

ADDRESSES: Written requests for copies of the summary of safety and effectiveness data and petitions for administrative review to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Robert Phillips, Center for Devices and Radiological Health (HFZ–470), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301–594–1212.

SUPPLEMENTARY INFORMATION: On February 5, 1991, Molecular Biosystems, Inc., San Diego, CA 92121, submitted to CDRH an application for premarket approval of Albunex®. The device, which is a suspension of air-filled microspheres made from sonicated 5 percent human albumin, is an ultrasound contrast media that is used as an aid for ultrasound contrast enhancement of ventricular chambers and improvement of endocardial border definition in patients with suboptimal echoes undergoing ventricular function and regional wall motion studies.

On July 29, 1992, the Radiological Devices Panel of the Medical Devices Advisory Committee, an FDA advisory committee, reviewed and recommended approval of the application. On August